You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SAR650984

Showing 1 - 25 of 31
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial in United States (Isatuximab, Carfilzomib, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Isatuximab
  • +2 more
  • San Francisco, California
  • +3 more
Dec 24, 2022

Plasma Cell Myeloma Trial in United States (isatuximab SAR650984, lenalidomide, dexamethasone)

Active, not recruiting
  • Plasma Cell Myeloma
  • isatuximab SAR650984
  • +2 more
  • San Francisco, California
  • +4 more
Jun 16, 2022

Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Rapid Infusion Isatuximab)

Withdrawn
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Rapid Infusion Isatuximab
  • (no location specified)
Jul 3, 2022

Multiple Myeloma Trial in Houston (Isatuximab, lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • Houston, Texas
    M D Anderson Cancer Center
Mar 8, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jun 14, 2022

Plasma Cell Myeloma Trial (Isatuximab (SAR650984), Cemiplimab (SAR439684), Dexamethasone)

Not yet recruiting
  • Plasma Cell Myeloma
  • Isatuximab (SAR650984)
  • +4 more
  • (no location specified)
Feb 1, 2023

Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma Trial in Boston (Isatuximab, Belantamab mafodotin, Pomalidomide)

Not yet recruiting
  • Relapsed Cancer
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jun 19, 2023

Multiple Myeloma Trial in Milwaukee (Isatuximab (for run-in portion), Isatuximab (for expansion), Pomalidomide)

Recruiting
  • Multiple Myeloma
  • Isatuximab (for run-in portion)
  • +4 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
Feb 18, 2022

Immune System Disorder Trial in Spain, United States (Isatuximab SAR650984, Acetaminophen (paracetamol) or equivalent,

Completed
  • Immune System Disorder
  • Isatuximab SAR650984
  • +5 more
  • San Francisco, California
  • +5 more
May 6, 2022

Multiple Myeloma Trial in Worldwide (isatuximab SAR650984 IV, pomalidomide, dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • isatuximab SAR650984 IV
  • +4 more
  • Gilbert, Arizona
  • +14 more
May 6, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Dexamethasone, Isatuximab)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Plasma Cell Myeloma Trial in Worldwide (lenalidomide, bortezomib, cyclophosphamide)

Active, not recruiting
  • Plasma Cell Myeloma
  • Nantes Cedex 01, France
  • +11 more
May 3, 2022

Tumor Trial in Worldwide (Isatuximab SAR650984, Atezolizumab)

Completed
  • Neoplasm
  • Santa Monica, California
  • +26 more
Jun 8, 2022

Multiple Myeloma Trial in Beijing, Nanjing, Tianjin (Isatuximab SAR650984)

Active, not recruiting
  • Multiple Myeloma
  • Isatuximab SAR650984
  • Beijing, China
  • +2 more
Aug 22, 2022

Plasma Cell Myeloma Trial in Czechia, France, United States (Isatuximab)

Completed
  • Plasma Cell Myeloma
  • Scottsdale, Arizona
  • +17 more
Apr 22, 2022

Plasma Cell Myeloma Trial in United States (Isatuximab SAR650984, Pomalidomide, Dexamethasone)

Completed
  • Plasma Cell Myeloma
  • Isatuximab SAR650984
  • +2 more
  • Scottsdale, Arizona
  • +12 more
Jul 8, 2021

Prostate Cancer, NSCLC Trial in Worldwide (Isatuximab SAR650984, Cemiplimab REGN2810)

Terminated
Has Results
  • Prostate Cancer
  • Non-small Cell Lung Cancer
  • Isatuximab SAR650984
  • Cemiplimab REGN2810
  • Birmingham, Alabama
  • +15 more
Apr 21, 2022

Multiple Myeloma Trial in Chicago, Milwaukee (Bortezomib, Isatuximab, Cyclophosphamide)

Recruiting
  • Multiple Myeloma
  • Chicago, Illinois
  • +1 more
Mar 14, 2022

AL Amyloidosis Trial in United States (Bortezomib, Cyclophosphamide, Dexamethasone)

Recruiting
  • AL Amyloidosis
  • Orange, California
  • +5 more
May 3, 2022

Plasma Cell Myeloma Recurrent Trial in Australia, Chile (Isatuximab IV, Isatuximab SC, Dexamethasone)

Recruiting
  • Plasma Cell Myeloma Recurrent
  • Isatuximab IV
  • +3 more
  • Salt Lake City, Utah
  • +33 more
Jan 16, 2023

Multiple Myeloma Trial in Japan (Isatuximab SAR650984)

Completed
  • Multiple Myeloma
  • Isatuximab SAR650984
  • Nagoya-shi, Aichi, Japan
  • +12 more
Nov 22, 2022

Plasma Cell Myeloma Refractory Trial in Worldwide (Isatuximab SAR650984, Dexamethasone, Pomalidomide)

Recruiting
  • Plasma Cell Myeloma Refractory
  • Isatuximab SAR650984
  • +4 more
  • Chicago, Illinois
  • +18 more
Aug 2, 2022

Warm Autoimmune Hemolytic Anemia (wAIHA) Trial in Worldwide (Isatuximab SAR650984)

Recruiting
  • Warm Autoimmune Hemolytic Anemia (wAIHA)
  • Isatuximab SAR650984
  • Los Angeles, California
  • +8 more
Mar 16, 2022

Plasma Cell Myeloma Trial in Worldwide (Isatuximab SAR650984, Bortezomib, Lenalidomide)

Active, not recruiting
  • Plasma Cell Myeloma
  • Isatuximab SAR650984
  • +3 more
  • Fort Myers, Florida
  • +103 more
Nov 3, 2022

T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia Trial in Worldwide (Isatuximab SAR650984,

Terminated
Has Results
  • T-cell Type Acute Leukemia-Precursor
  • T-lymphoblastic Lymphoma/Leukaemia
  • Isatuximab SAR650984
  • +4 more
  • Atlanta, Georgia
  • +16 more
Mar 10, 2022